Literature DB >> 21487606

The synthetic genetic interaction network reveals small molecules that target specific pathways in Sacchromyces cerevisiae.

Craig M Tamble1, Robert P St Onge, Guri Giaever, Corey Nislow, Alexander G Williams, Joshua M Stuart, R Scott Lokey.   

Abstract

High-throughput elucidation of synthetic genetic interactions (SGIs) has contributed to a systems-level understanding of genetic robustness and fault-tolerance encoded in the genome. Pathway targets of various compounds have been predicted by comparing chemical-genetic synthetic interactions to a network of SGIs. We demonstrate that the SGI network can also be used in a powerful reverse pathway-to-drug approach for identifying compounds that target specific pathways of interest. Using the SGI network, the method identifies an indicator gene that may serve as a good candidate for screening a library of compounds. The indicator gene is selected so that compounds found to produce sensitivity in mutants deleted for the indicator gene are likely to abrogate the target pathway. We tested the utility of the SGI network for pathway-to-drug discovery using the DNA damage checkpoint as the target pathway. An analysis of the compendium of synthetic lethal interactions in yeast showed that superoxide dismutase 1 (SOD1) has significant SGI connectivity with a large subset of DNA damage checkpoint and repair (DDCR) genes in Saccharomyces cerevisiae, and minimal SGIs with non-DDCR genes. We screened a sod1Δ strain against three National Cancer Institute (NCI) compound libraries using a soft agar high-throughput halo assay. Fifteen compounds out of ∼3100 screened showed selective toxicity toward sod1Δ relative to the isogenic wild type (wt) strain. One of these, 1A08, caused a transient increase in growth in the presence of sublethal doses of DNA damaging agents, suggesting that 1A08 inhibits DDCR signaling in yeast. Genome-wide screening of 1A08 against the library of viable homozygous deletion mutants further supported DDCR as the relevant targeted pathway of 1A08. When assayed in human HCT-116 colorectal cancer cells, 1A08 caused DNA-damage resistant DNA synthesis and blocked the DNA-damage checkpoint selectively in S-phase.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487606      PMCID: PMC4653045          DOI: 10.1039/c0mb00298d

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  39 in total

Review 1.  Cell cycle control as a basis for cancer drug development (Review).

Authors:  E R McDonald; W S El-Deiry
Journal:  Int J Oncol       Date:  2000-05       Impact factor: 5.650

2.  Cell-based assays for identification of novel double-strand break-inducing agents.

Authors:  Heather M Dunstan; Catherine Ludlow; Sondra Goehle; Michelle Cronk; Philippe Szankasi; David R H Evans; Julian A Simon; John R Lamb
Journal:  J Natl Cancer Inst       Date:  2002-01-16       Impact factor: 13.506

Review 3.  Inhibition of Hsp90: a multitarget approach to radiosensitization.

Authors:  Kevin Camphausen; Philip J Tofilon
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

4.  Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.

Authors:  Ainslie B Parsons; Andres Lopez; Inmar E Givoni; David E Williams; Christopher A Gray; Justin Porter; Gordon Chua; Richelle Sopko; Renee L Brost; Cheuk-Hei Ho; Jiyi Wang; Troy Ketela; Charles Brenner; Julie A Brill; G Esteban Fernandez; Todd C Lorenz; Gregory S Payne; Satoru Ishihara; Yoshikazu Ohya; Brenda Andrews; Timothy R Hughes; Brendan J Frey; Todd R Graham; Raymond J Andersen; Charles Boone
Journal:  Cell       Date:  2006-08-11       Impact factor: 41.582

5.  The chemical genomic portrait of yeast: uncovering a phenotype for all genes.

Authors:  Maureen E Hillenmeyer; Eula Fung; Jan Wildenhain; Sarah E Pierce; Shawn Hoon; William Lee; Michael Proctor; Robert P St Onge; Mike Tyers; Daphne Koller; Russ B Altman; Ronald W Davis; Corey Nislow; Guri Giaever
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

6.  Mutagenicity of anti-cancer nitrobenzofuroxans.

Authors:  S Thompson; L Kellicutt
Journal:  Mutat Res       Date:  1977-04       Impact factor: 2.433

7.  Genomic profiling of drug sensitivities via induced haploinsufficiency.

Authors:  G Giaever; D D Shoemaker; T W Jones; H Liang; E A Winzeler; A Astromoff; R W Davis
Journal:  Nat Genet       Date:  1999-03       Impact factor: 38.330

8.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

Review 9.  Cell cycle checkpoints and their impact on anticancer therapeutic strategies.

Authors:  Alan Eastman
Journal:  J Cell Biochem       Date:  2004-02-01       Impact factor: 4.429

10.  The BioGRID Interaction Database: 2008 update.

Authors:  Bobby-Joe Breitkreutz; Chris Stark; Teresa Reguly; Lorrie Boucher; Ashton Breitkreutz; Michael Livstone; Rose Oughtred; Daniel H Lackner; Jürg Bähler; Valerie Wood; Kara Dolinski; Mike Tyers
Journal:  Nucleic Acids Res       Date:  2007-11-13       Impact factor: 16.971

View more
  3 in total

1.  A Chemogenomic Screening Platform Used to Identify Chemotypes Perturbing HSP90 Pathways.

Authors:  Fiona M Thomas; Kourtney M Goode; Bartek Rajwa; Andrew A Bieberich; Larisa V Avramova; Tony R Hazbun; V Jo Davisson
Journal:  SLAS Discov       Date:  2017-01-31       Impact factor: 3.341

Review 2.  Efforts to make and apply humanized yeast.

Authors:  Jon M Laurent; Jonathan H Young; Aashiq H Kachroo; Edward M Marcotte
Journal:  Brief Funct Genomics       Date:  2015-10-13       Impact factor: 4.241

3.  Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.

Authors:  Sirin Theerawatanasirikul; Chih Jung Kuo; Nanthawan Phecharat; Jullada Chootip; Chalermpol Lekcharoensuk; Porntippa Lekcharoensuk
Journal:  Antiviral Res       Date:  2020-09-07       Impact factor: 5.970

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.